Product image of Minims Oxybuprocainhydrochlorid Bausch + Lomb Ireland Limited (Oxybuprocaine Hydrochloride) supplied by GNH India

Minims Oxybuprocainhydrochlorid Bausch + Lomb Ireland Limited

Active Ingredient:
Oxybuprocaine Hydrochloride
Origin:
EU

Minims Oxybuprocainhydrochlorid Bausch + Lomb Ireland Limited (Oxybuprocaine Hydrochloride)

Oxybuprocaine Hydrochloride, the active ingredient in Minims Oxybuprocainhydrochlorid, is an ester‑type local anesthetic presented as a sterile ophthalmic solution for topical ocular use. It produces reversible surface anesthesia of the cornea and conjunctiva, facilitating diagnostic examinations and minor therapeutic procedures on the eye.

GNH India supplies Minims Oxybuprocainhydrochlorid as a licensed, GDP‑compliant international pharmaceutical product, providing the formulation to hospitals, pharmacies and clinics worldwide under EU‑market standards. The company ensures quality control, regulatory compliance and reliable logistics where required.

Manufacturer / TM Owner

Bausch + Lomb Ireland Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Oxybuprocaine Hydrochloride is used as a topical ocular anesthetic to temporarily block sensation in the eye.
  • Diagnostic ocular examinations: provides surface anesthesia to allow slit‑lamp or fundus evaluation without discomfort.
  • Minor ocular surgical procedures: facilitates anesthesia for foreign body removal, laser treatment, or minor incisions.
  • Therapeutic eye interventions: prepares the eye for drug administration or minor therapeutic manipulations.

How It Works

  • Oxybuprocaine Hydrochloride acts by reversibly binding to voltage‑gated sodium channels on peripheral nerve membranes in the cornea and conjunctiva. This blockade prevents the influx of sodium ions, inhibiting the initiation and propagation of nerve impulses, thereby producing a rapid, localized loss of sensation without affecting deeper ocular structures.

Side Effects

Oxybuprocaine Hydrochloride may cause local ocular reactions and, rarely, systemic effects.

Common Side Effects

  • Transient burning or stinging: mild discomfort upon instillation
  • Redness of the conjunctiva: temporary hyperemia
  • Tearing: increased lacrimation
  • Blurred vision: short‑term visual disturbance
  • Foreign body sensation: feeling of grit
  • Mild allergic conjunctivitis: limited itching

Serious or Rare Side Effects

  • Corneal epithelial toxicity: rare ulceration or delayed healing
  • Severe allergic reaction: anaphylaxis or angioedema
  • Systemic toxicity: CNS depression or cardiac arrhythmia (extremely rare)
  • Persistent numbness: prolonged loss of sensation beyond expected duration

Precautions & Warnings

When using Minims Oxybuprocainhydrochlorid, consider the following precautions.

  • Allergy assessment: avoid use in patients with known hypersensitivity to oxybuprocaine or ester anesthetics
  • Contact lens wearers: remove lenses before administration to prevent drug retention
  • Pre‑existing corneal disease: use with caution in keratitis or epithelial defects
  • Pediatric use: limit to recommended indications and monitor closely
  • Repeated dosing: avoid frequent applications to reduce risk of toxicity
  • Store at room temperature: keep container tightly closed, protect from light and moisture

Avoid Interactions

Oxybuprocaine Hydrochloride can interact with other medications; awareness of potential interactions is important.

Major Interactions (Avoid)

  • Systemic anesthetics: concurrent use may potentiate CNS depression
  • Beta‑blocker eye drops: may increase ocular hypotension
  • Other topical ocular anesthetics: additive local toxicity
  • Anticholinergic eye drops: may exacerbate dry eye
  • MAO inhibitors: theoretical risk of increased systemic effects

Moderate Interactions (Monitor Closely)

  • Antihistamine eye drops: may alter drug absorption
  • Topical antibiotics: monitor for delayed wound healing
  • Non‑steroidal anti‑inflammatory eye drops: watch for corneal toxicity

Frequently Asked Questions

It is a topical ocular anesthetic containing oxybuprocaine hydrochloride, used to provide temporary surface anesthesia of the cornea and conjunctiva during diagnostic eye examinations and minor ocular procedures.

It reversibly blocks voltage‑gated sodium channels in peripheral nerve membranes of the ocular surface, preventing nerve impulse initiation and propagation, resulting in rapid loss of sensation.

The dosing regimen is determined by the prescribing clinician based on the specific procedure and patient factors; typically a few drops are instilled in the affected eye shortly before the examination or procedure.

Safety data are limited; the product should be used during pregnancy or lactation only if the potential benefit justifies the potential risk, and the decision should be made by the healthcare professional.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Compared with amine‑type anesthetics such as proparacaine, oxybuprocaine is an ester‑type agent with a rapid onset and short duration, offering effective surface anesthesia with a lower risk of corneal toxicity when used appropriately.

The product should be stored at room temperature, kept in its original container, protected from light and moisture, and not frozen. Ensure the cap is tightly closed when not in use.

It is applied topically to the eye as sterile drops. The prescriber directs the number of drops and timing relative to the procedure; typically a drop is placed in the conjunctival sac a few minutes before the examination or intervention.

Rare but serious adverse events include corneal epithelial toxicity, severe allergic reactions such as anaphylaxis, and systemic toxicity leading to central nervous system depression or cardiac arrhythmias. Immediate medical attention is required if these occur.

Patients with known hypersensitivity to oxybuprocaine, other ester‑type anesthetics, or any component of the formulation should avoid use. It is also contraindicated in eyes with active corneal ulceration or severe epithelial defects.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Oxybuprocaine Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT